SiNtx Technologies, Inc. - SINT STOCK NEWS

SINTX Technologies has entered into a worldwide exclusive licensing agreement with O2TODAY to develop consumer masks integrated with SINTX’s silicon nitride, aimed at inactivating pathogens and combating COVID-19. The agreement spans two years with options for extension and entails a licensing fee and royalties based on sales. Both companies believe this partnership will position O2TODAY as a market leader in innovative masks. The demand for respiratory protection is projected to grow, with shipments expected to exceed 10 billion units by 2025.

SINTX Technologies celebrates its 25th anniversary in 2021, marking over 35,000 spinal implantations and leadership in silicon nitride manufacturing. The company focuses on three growth areas: antipathogenic applications, industrial uses, and biomedical opportunities. The pandemic increased demand for protective equipment, with the reusable mask market expected to reach $7.08 billion by 2027. SINTX plans to launch a consumer mask with antiviral properties in collaboration with O2TODAY. Additionally, the company targets a $174 billion industrial market with its silicon nitride innovations.

SINTX Technologies has provided a Q3 business update revealing revenues of $0.1 million for the quarter and $0.5 million for the year-to-date. Despite challenges from COVID-19, the company managed to avoid layoffs and even hired new staff. A significant reduction in losses was noted, with losses dropping from $0.68 per share in Q3 2019 to $0.11 per share in Q3 2020. The company is exploring new opportunities in medical and non-medical markets, including antipathogenic silicon nitride applications and aerospace components, following its AS9100D certification.

SINTX Technologies has entered a joint development agreement with Iwatani Corporation of America to integrate SINTX AP² silicon nitride powder into polymer materials. This collaboration aims to create antimicrobial surfaces for IT devices, potentially reducing the spread of respiratory diseases like SARS-CoV-2 and Influenza A. The development leverages promising data showing silicon nitride's effectiveness against viruses. Both companies plan to fund product development in both the U.S. and Japan. SINTX emphasizes this partnership as a significant step towards new product offerings and revenue generation.

SINTX Technologies has achieved AS9100D certification for its Quality Management System, allowing the company to supply components to the aviation, space, and defense markets. Certified by the British Standards Institute on October 28, 2020, SINTX's compliance with AS9100D enables listing in the OASIS database, used by major aerospace companies like Boeing and Lockheed Martin for supplier selection. In addition to AS9100D, SINTX maintains ISO 9001:2015 and ISO 13485:2016 certifications, underscoring its commitment to stringent quality standards across sectors.

SINTX Technologies has secured US Patent 10,806,831, which covers antibacterial biomedical implants utilizing silicon nitride. This patent expands the company's capability to enhance the antibacterial properties of various implants, including those made from PEEK and titanium. The company plans to launch a composite product in early 2021. SINTX's silicon nitride can also be used in face masks to neutralize pathogens. This patent strengthens SINTX's intellectual property position in the biomedical sector.

SINTX Technologies, Inc. (NASDAQ: SINT) has announced progress in the development of a "catch-and-kill" mask designed to inactivate respiratory viruses, including SARS-CoV-2. The company has successfully embedded silicon nitride particles into fabric, marking a significant step in mask production. The next phases involve fabric testing and manufacturing scale-up. Dr. Bal, CEO of SINTX, emphasizes the mask's potential market beyond COVID-19, addressing air quality concerns in densely populated areas. Collaboration with O2TODAY aims to bring this innovative mask to market, enhancing public health safety.

SINTX Technologies has appointed Michael Marcroft as Vice President of Business Development, focusing on the medical device sector. With nearly 20 years of experience from companies like 3M and Medtronic, Marcroft aims to leverage the potential of silicon nitride, a key biomaterial. Dr. Sonny Bal, CEO, expressed confidence that Marcroft's expertise will open new market opportunities. SINTX, specializing in silicon nitride ceramics, is positioned for growth in diverse medical applications, including arthroplasty and dental implants.

SINTX Technologies (NASDAQ: SINT) announced the filing of a universal shelf registration statement on Form S-3 with the SEC. The filing allows SINTX to access capital markets in the future up to $75 million, enhancing financial flexibility for growth opportunities. While there are no immediate plans to issue securities, this move is considered prudent for standard corporate governance. The registration statement has not yet become effective, and sales will only occur following its effectiveness.